BRIEF—Nielsen grants Maruho rights to common warts treatment in Japan

Privately-held, San Diego-based Nielsen BioSciences has granted Japanese dermatology specialist Maruho exclusive rights to market CANDIN in Japan for the treatment of Verruca vulgaris (common warts).

Enrollment in Nielsen’s Phase III trial of the treatment is expected to begin in the second half of 2023. There are no treatments for common warts approved in the USA at present.

Under the terms of the license agreement, Maruho receives an exclusive license for the post-launch sales and promotional activities of CANDIN in Japan after it is developed by Nielsen and approved by regulatory authorities.

Maruho will pay Nielsen a undisclosed upfront payment, and additional development, regulatory and sales milestone payments based on outcomes.

With the upfront payment and milestones, Nielsen has the potential to earn more than $100 million from the license agreement.